Use of nicotine replacement therapy in socioeconomically deprived young smokers: a community-based pilot randomised controlled trial.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Smoking is common in young people, particularly in disadvantaged groups, and continued smoking has a major impact on quality and quantity of life.

Who Took Part

By PubMed's age tags, the people studied were children, teenagers and adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and pilot.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

The researchers surveyed smoking prevalence and attitudes to smoking and quitting in young people accessing an open access youth project in a deprived area of Nottingham, and used the information gained to design a community based smoking cessation service incorporating a randomised controlled trial of nicotine patches against placebo given in association with individual behavioural support.

The researchers resurveyed smoking prevalence among project attendees after completing the pilot study.

What Was Measured

PubMed files the paper under topics including Administration, Cutaneous, Counseling, Nicotine, Pilot Projects, Poverty Areas, Smoking Cessation and United Kingdom.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Tobacco control), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.